Document is current
Any future updates will be listed below
-
Authors
Mathews, Maju
Pei, Huiling
Savitz, Adam
Nuamah, Isaac
Hough, David
Alphs, Larry
Gopal, Srihari
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01515423 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
https://doi.org/10.1007/s40262-016-0459-3
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
https://doi.org/10.1007/s40261-018-0647-z
-
Funding
Funding for this research was provided by:
Janssen Research & Development, LLC, Raritan, NJ, USA
- License Information
-
More Information
Article History
First Online: 7 June 2018
Compliance with Ethical Standards
:
: The study protocol and amendments were reviewed by an Independent Ethics Committee or Institutional Review Board for each site. The study was conducted in compliance with the Declaration of Helsinki and applicable regulatory requirements. Written informed consent was obtained from all patients before study enrollment.
: All authors are employees of Janssen Research & Development and hold stock in the company.
: This study was funded by Janssen Research & Development, LLC, Raritan, NJ, USA.
